(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
India’s delayed climate plan sets modest emission target - 237 Things Just Individuals Experiencing childhood during the 80s Will Comprehend
- 36 Fun Urban areas For Seniors To Travel
- 4Nikki Glaser has been testing out Golden Globes jokes. There's one nobody wants to hear
- 5Renewables cover over 50% of German electricity consumption in Q1
- Single women risk rape and exploitation in search for better life in Europe
- Ford Is Using a Chinese-Built Van to Fight Europe’s EV Price War
- Christopher Nolan's 'The Odyssey' trailer: See Anne Hathaway, Matt Damon and Tom Holland in 1st look at movie
- Vote in favor of your Number one kind of juice
- Plane Passenger Allegedly Includes ‘Bomb Threat’ in Hotspot Network Name, Forces Flight to Make Emergency Landing
- Pick Your Number one breakfast food
- 15 Preposterous Cosplay Ensembles That Will Blow You Away
- Best Exciting ride: Which One Rushes You the Most?
- When preventable infections turn deadly behind bars | The Excerpt
